Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Wangyang You"'
Autor:
Yanxia Wang, Gang Shi, Xue Wang, Zhiqiang Xie, Jinbo Gou, Lili Huang, Haitao Huang, Wangyang You, Ruijie Wang, Yongli Yang, Feiyu Wang, Tao Zhu, Dongyang Zhao
Publikováno v:
Vaccines, Vol 12, Iss 8, p 827 (2024)
Background: Protein-based pneumococcal vaccines (PBPVs) may offer expanded protection against Streptococcus pneumoniae and tackle the antimicrobial resistance crisis in pneumococcal infections. This study examined the safety and immunogenicity in hea
Externí odkaz:
https://doaj.org/article/ee3a3fbf1dcc4e329bc5f4f9652f3231
Autor:
Guangwei Feng, Deyu Jiang, Weixiao Han, Zhiqiang Xie, Zhiwei Jiang, Lili Huang, Jianfeng Wang, Wei Zhang, Li Xu, Jiebing Tan, Wangyang You, Guoliang Cui, Changgui Li, Yanxia Wang
Publikováno v:
International Journal of Infectious Diseases, Vol 130, Iss , Pp 20-27 (2023)
ABSTRACT: Objectives: To evaluate the safety, immunogenicity, and lot-to-lot consistency of Sabin strain-based inactivated polio vaccine (sIPV) in a five-dose vial presentation. Methods: Stage I was an open-label safety observation, in which 72 healt
Externí odkaz:
https://doaj.org/article/d0be7cecfa744464b5969ca6aebff923
Autor:
Guangwei Feng, Ming Shao, Jianfeng Wang, Lili Huang, Jian Tan, Zhiwei Jiang, Wangyang You, Yurong Li, Yonghui Yang, Jing Li, Yanxia Wang
Publikováno v:
Vaccines, Vol 12, Iss 2, p 123 (2024)
Background: The multidose Sabin-strain inactivated poliovirus vaccine (sIPV) has the potential to significantly aid in the eradication of poliomyelitis, particularly in low- and middle-income countries. As part of a phase III clinical trial in which
Externí odkaz:
https://doaj.org/article/1d3d6db04e6f455ba96f2b2c78d08b12
Autor:
Shengli Xia, Kai Duan, Yuntao Zhang, Xiaoqing Zeng, Dongyang Zhao, Huajun Zhang, Zhiqiang Xie, Xinguo Li, Cheng Peng, Wei Zhang, Yunkai Yang, Wei Chen, Xiaoxiao Gao, Wangyang You, Xuewei Wang, Zejun Wang, Zhengli Shi, Yanxia Wang, Xuqin Yang, Qingliang Li, Lili Huang, Qian Wang, Jia Lu, Yongli Yang, Jing Guo, Wei Zhou, Xin Wan, Cong Wu, Wenhui Wang, Shihe Huang, Jianhui Du, Xuanxuan Nian, Tao Deng, Zhiming Yuan, Shuo Shen, Wanshen Guo, Jia Liu, Xiaoming Yang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in participants aged 3-17 years. A randomized, double-blin
Externí odkaz:
https://doaj.org/article/5b326192475e42548f685b32e2bddb9b
Autor:
Wanshen Guo, Kai Duan, Yuntao Zhang, Zhiming Yuan, Yan-Bo Zhang, Zejun Wang, Dongyang Zhao, Huajun Zhang, Zhiqiang Xie, Xinguo Li, Cheng Peng, Wei Zhang, Yunkai Yang, Wei Chen, Xiaoxiao Gao, Wangyang You, Xue-Wei Wang, Zhengli Shi, Yanxia Wang, Xu-Qin Yang, Lianghao Zhang, Lili Huang, Qian Wang, Jia Lu, Yong-Li Yang, Jing Guo, Wei Zhou, Xin Wan, Cong Wu, Wenhui Wang, Jianhui Du, Xuanxuan Nian, Xing-Hang Li, Shihe Huang, Shuo Shen, Shengli Xia, An Pan, Xiaoming Yang
Publikováno v:
EClinicalMedicine, Vol 38, Iss , Pp 101010- (2021)
Background: We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged ≥18 years. Methods: This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healt
Externí odkaz:
https://doaj.org/article/1b71663a474248c885eee1d36a81c010
Autor:
Yukai Zhang, Lei Wang, Yanxia Wang, Wei Zhang, Ningning Jia, Zhiqiang Xie, Lili Huang, Wangyang You, Weifeng Lu, Erwei Li, Feilong Gao, Yuansheng Hu, Fanhong Meng, Shengli Xia
Publikováno v:
Vaccines, Vol 10, Iss 5, p 660 (2022)
Aim: To evaluate the immunogenicity and safety of a booster dose of live attenuated varicella vaccine (VarV) manufactured by Sinovac (Dalian) Vaccine Technology Co. Ltd., and the immune persistence of a primary dose in 2- to 6-year-old children. Meth
Externí odkaz:
https://doaj.org/article/8381a868e45d48edb71edb95bf0d19bc
Autor:
Yuhui, Zhang, Yanxia, Wang, Chunyu, Jia, Guangfu, Li, Wei, Zhang, Qin, Li, Xiaofen, Chen, Wenna, Leng, Lili, Huang, Zhiqiang, Xie, Huiping, Zhang, Wangyang, You, Rui, An, Hongyan, Jiang, Xue, Zhao, Siyan, Cheng, Jiebing, Tan, Weiyang, Cui, Feilong, Gao, Weifeng, Lu, Yuping, Wang, Yongli, Yang, Shengli, Xia, Shuai, Wang
Publikováno v:
Vaccine. 40:4933-4941
Subunit influenza vaccine only formulated with surface antigen proteins has better safety profiles relative to split-virion influenza vaccine. Compared to the traditional quadrivalent split-virion influenza vaccine, a novel quadrivalent subunit influ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b1fbd4c4617b2e3c580b7905c81d878
https://doi.org/10.1016/j.vaccine.2022.06.078
https://doi.org/10.1016/j.vaccine.2022.06.078
Autor:
Lili Huang, Zhen Chen, Yufei Song, Jiebing Tan, Ningning Jia, Wangyang You, Hongxue Yuan, Guang-Wei Feng, Changgui Li, Chunfang Luan, Yaru Quan, Yanxia Wang
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68174fb5e14897dd1c910ea031196a73
https://doi.org/10.2139/ssrn.4447572
https://doi.org/10.2139/ssrn.4447572
Autor:
Wei Wang, Islam Eltantawy, Yuxiu Zhao, Hui Wang, Salah Eldin Hussein, Majed Al Nusair, Shamma K Al Mazrouei, Jaleela S Jawad, Walid Abbas Zaher, Yan-Bo Zhang, Sally Mahmoud, Xinguo Li, Shengli Xia, Wei Chen, Guoqing Zhao, Zhiqiang Xie, Wangyang You, Yuntao Zhang, Xuqin Yang, Tian Yang, Xiaoming Yang, Zaidoon M Hussain, Peng Xiao, Maysoon Al Karam, An Pan, Manaf M Al Qahtani, Najiba Abdulrazzaq, Mohammed Saifuddin Fasihuddin, Rui Ma, Kai Duan, Tehmina Khan, Mohamed Hassany, Shihe Huang, Nawal Al Kaabi, Jehad Abdalla, Yunkai Yang, Qian Wang, Bonan Lai, Ashish Koshy, Liu Yang, Zhiwei Jiang
Publikováno v:
JAMA
IMPORTANCE: Although effective vaccines against COVID-19 have been developed, additional vaccines are still needed. OBJECTIVE: To evaluate the efficacy and adverse events of 2 inactivated COVID-19 vaccines. DESIGN, SETTING, AND PARTICIPANTS: Prespeci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce202b4e5ecd76b0f29f14e21a6ad047
https://europepmc.org/articles/PMC8156175/
https://europepmc.org/articles/PMC8156175/
Autor:
Lili Huang, Shihe Huang, Wenhui Wang, Wei Zhang, Shengli Xia, Xiaoxiao Gao, Wei Chen, Wangyang You, Wanshen Guo, Xing-Hang Li, Zhiming Yuan, Du Jianhui, Xin Wan, Wei Zhou, Shuo Shen, Xiaoming Yang, Zhiqiang Xie, Huajun Zhang, Zhengli Shi, Dongyang Zhao, Cheng Peng, Yongli Yang, Cong Wu, Lianghao Zhang, Zejun Wang, Xue-Wei Wang, Y. Wang, Yan-Bo Zhang, Yuntao Zhang, Xinguo Li, Yunkai Yang, Qian Wang, Jia Lu, Xuanxuan Nian, Xuqin Yang, Jing Guo, Kai Duan, An Pan
Publikováno v:
EClinicalMedicine
EClinicalMedicine, Vol 38, Iss, Pp 101010-(2021)
EClinicalMedicine, Vol 38, Iss, Pp 101010-(2021)
Background We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged ≥18 years. Methods This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healthy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::129b021059ed9eb2c747090397e14876
https://pubmed.ncbi.nlm.nih.gov/34250456
https://pubmed.ncbi.nlm.nih.gov/34250456